Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (121-130 of 184) with videos related to

Pageof 19
Sort By:
AIDS (London, England)|February 21, 2012
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialSarah B Lorenzana, Michael D Hughes, Beatriz Grinsztejn, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
Journal of Virology|February 14, 2004
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionAndrew J Leigh Brown, Simon D W Frost, Benjamin Good, et al.
Virology|March 4, 2008
Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B virusesYi Liu, Marcel E Curlin, Kurt Diem, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Therapeutic amprenavir concentrations in cerebrospinal fluidDavid Croteau, Scott Letendre, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix, Ann C Collier, Michael M Lederman, et al.
The Journal of Infectious Diseases|August 22, 2020
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral TherapyRajesh T Gandhi, Joshua C Cyktor, Ronald J Bosch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 5, 2011
Neurocognitive impact of substance use in HIV infectionDesiree A Byrd, Robert P Fellows, Susan Morgello, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2012
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovirBrookie M Best, Scott L Letendre, Peter Koopmans, et al.
Pageof 19

Showing results (121-130 of 184) with videos related to

Sort By:
Pageof 19
AIDS (London, England)|February 21, 2012
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialSarah B Lorenzana, Michael D Hughes, Beatriz Grinsztejn, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
Journal of Virology|February 14, 2004
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionAndrew J Leigh Brown, Simon D W Frost, Benjamin Good, et al.
Virology|March 4, 2008
Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B virusesYi Liu, Marcel E Curlin, Kurt Diem, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Therapeutic amprenavir concentrations in cerebrospinal fluidDavid Croteau, Scott Letendre, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix, Ann C Collier, Michael M Lederman, et al.
The Journal of Infectious Diseases|August 22, 2020
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral TherapyRajesh T Gandhi, Joshua C Cyktor, Ronald J Bosch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 5, 2011
Neurocognitive impact of substance use in HIV infectionDesiree A Byrd, Robert P Fellows, Susan Morgello, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2012
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovirBrookie M Best, Scott L Letendre, Peter Koopmans, et al.
Pageof 19